$ELOX
Eloxx Pharmaceuticals, Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021055313 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.035M $3.070M
YoY Change 64.01% -48.66%
% of Gross Profit
Research & Development $5.210M $3.400M
YoY Change 53.24% -50.01%
% of Gross Profit
Depreciation & Amortization $30.00K $16.00K
YoY Change 87.5% -11.11%
% of Gross Profit
Operating Expenses $10.25M $6.296M
YoY Change 62.72% -50.73%
Operating Profit -$10.25M -$6.296M
YoY Change 62.72% -50.73%
Interest Expense -$180.0K -$320.0K
YoY Change -43.75% 220.0%
% of Operating Profit
Other Income/Expense, Net $360.0K -$321.0K
YoY Change -212.15% 234.38%
Pretax Income -$9.885M -$6.620M
YoY Change 49.32% -48.6%
Income Tax
% Of Pretax Income
Net Earnings -$9.885M -$6.617M
YoY Change 49.39% -48.61%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11
Diluted Earnings Per Share -$114.7K -$164.9K
COMMON SHARES
Basic Shares Outstanding 86.21M
Diluted Shares Outstanding 86.21M

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $52.43M $30.59M
YoY Change 71.4% -52.89%
Cash & Equivalents $52.43M $30.59M
Short-Term Investments
Other Short-Term Assets $1.110M $1.620M
YoY Change -31.48% 6.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $53.54M $32.21M
YoY Change 66.23% -51.82%
LONG-TERM ASSETS
Property, Plant & Equipment $224.0K $149.0K
YoY Change 50.34% -86.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $30.00K
YoY Change -100.0% -72.73%
Total Long-Term Assets $1.841M $732.0K
YoY Change 151.5% -39.5%
TOTAL ASSETS
Total Short-Term Assets $53.54M $32.21M
Total Long-Term Assets $1.841M $732.0K
Total Assets $55.38M $32.94M
YoY Change 68.12% -51.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.509M $638.0K
YoY Change 293.26% -62.25%
Accrued Expenses $2.611M $3.091M
YoY Change -15.53% -44.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $4.917M
YoY Change -100.0% 40.89%
Total Short-Term Liabilities $9.510M $9.990M
YoY Change -4.8% -11.04%
LONG-TERM LIABILITIES
Long-Term Debt $11.91M $7.823M
YoY Change 52.26% -30.11%
Other Long-Term Liabilities $964.0K $60.00K
YoY Change 1506.67% -85.37%
Total Long-Term Liabilities $11.91M $7.823M
YoY Change 52.26% -30.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.510M $9.990M
Total Long-Term Liabilities $11.91M $7.823M
Total Liabilities $22.39M $17.86M
YoY Change 25.31% -21.75%
SHAREHOLDERS EQUITY
Retained Earnings -$226.2M -$165.5M
YoY Change 36.68%
Common Stock $182.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.00M $15.08M
YoY Change
Total Liabilities & Shareholders Equity $55.38M $32.94M
YoY Change 68.12% -51.6%

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$9.885M -$6.617M
YoY Change 49.39% -48.61%
Depreciation, Depletion And Amortization $30.00K $16.00K
YoY Change 87.5% -11.11%
Cash From Operating Activities -$7.588M -$5.260M
YoY Change 44.26% -53.53%
INVESTING ACTIVITIES
Capital Expenditures -$69.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $6.750M
YoY Change -100.0% -142.97%
Cash From Investing Activities -$69.00K $6.750M
YoY Change -101.02% -142.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.355M -1.250M
YoY Change -368.4% 941.67%
NET CHANGE
Cash From Operating Activities -7.588M -5.260M
Cash From Investing Activities -69.00K 6.750M
Cash From Financing Activities 3.355M -1.250M
Net Change In Cash -4.302M 240.0K
YoY Change -1892.5% -100.88%
FREE CASH FLOW
Cash From Operating Activities -$7.588M -$5.260M
Capital Expenditures -$69.00K
Free Cash Flow -$7.519M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y10M28D
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86208754
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40142178
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
64428187
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9885000
elox Restructuring Charges Includes Stock Based Compensation
RestructuringChargesIncludesStockBasedCompensation
3994000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40115351
us-gaap Net Income Loss
NetIncomeLoss
-54637000
us-gaap Net Income Loss
NetIncomeLoss
-28450000
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-13000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-18000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6630000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54637000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28468000
us-gaap Profit Loss
ProfitLoss
-54637000
us-gaap Profit Loss
ProfitLoss
-28450000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
22670000
us-gaap Share Based Compensation
ShareBasedCompensation
7567000
us-gaap Share Based Compensation
ShareBasedCompensation
7385000
us-gaap Depreciation
Depreciation
86000
us-gaap Depreciation
Depreciation
52000
elox Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
672000
elox Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
373000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
298000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
438000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-15000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6617000
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
22335000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47718000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-36058000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
40643000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-84000
elox Gain On Extinguishment Of Debt
GainOnExtinguishmentOfDebt
808000
elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
268000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-631000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
137000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
410000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1233000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-649000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1569000
us-gaap Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
1003000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-659000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-372000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25070000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23498000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
2145000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
69000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
33750000
us-gaap Payments For Proceeds From Longterm Investments
PaymentsForProceedsFromLongtermInvestments
-42000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2076000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33792000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47718000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
11910000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
797000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
11383000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3333000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
238000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
122000
elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
2918000
elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
402000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
23000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
70000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50948000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2186000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27954000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8108000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24724000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22536000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52432000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30592000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
246000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
52000
us-gaap Stock Issued1
StockIssued1
22335000
us-gaap Interest Paid Net
InterestPaidNet
415000
us-gaap Interest Paid Net
InterestPaidNet
665000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10230000
CY2021Q1 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-94000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1308000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8694000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2224000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9885000
CY2021Q3 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-1000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
32998000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
36213000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64000
CY2020Q3 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-3000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1415000
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-13000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6617000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
15078000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-226200000
CY2021Q3 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
52400000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2900000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11700000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3400000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11900000
CY2021Q3 elox Prepaid Financing Costs
PrepaidFinancingCosts
211000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
369000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
368000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
864000
CY2021Q3 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
12000
CY2020Q4 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
631000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
272000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
170000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1936183
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5732092
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.53
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
23491
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1169000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
368000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
446000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
144000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
313000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
224000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
133000
CY2021Q3 us-gaap Depreciation
Depreciation
30000
CY2020Q3 us-gaap Depreciation
Depreciation
16000
us-gaap Depreciation
Depreciation
86000
us-gaap Depreciation
Depreciation
52000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1278186
CY2021Q3 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
396000
CY2020Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
802000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1188000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1315000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
819000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
415000
CY2021Q3 elox Accrued Interest On Debt
AccruedInterestOnDebt
3000
CY2020Q4 elox Accrued Interest On Debt
AccruedInterestOnDebt
57000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
205000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
77000
CY2020Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
258000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2611000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2924000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4204000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6101000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2195000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12500000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1408000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
11092000
CY2021Q3 elox Long Term Debt Maturities Final Fee Due
LongTermDebtMaturitiesFinalFeeDue
-819000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11911000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.38
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8233476
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.61
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
797433
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2821635
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.47
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
387049
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
323892
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
323892
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.31
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.31
elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P1Y11M26D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3803061
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.16
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2224000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1414000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7567000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7385000
CY2021Q3 elox Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost
CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost
52400000
CY2021Q3 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
52400000
CY2020Q4 elox Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost
CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost
24700000
CY2020Q4 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
24700000
CY2021Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
elox Fair Value Assets Transfers Between Level2 And Level3 Description
FairValueAssetsTransfersBetweenLevel2AndLevel3Description
the Company did not have any transfers of financial assets between levels
CY2020Q3 us-gaap Interest Expense Other
InterestExpenseOther
327000
us-gaap Interest Expense Other
InterestExpenseOther
803000
us-gaap Interest Expense Other
InterestExpenseOther
1090000
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
36000
CY2020Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
23000
us-gaap Interest And Other Income
InterestAndOtherIncome
36000
us-gaap Interest And Other Income
InterestAndOtherIncome
336000
CY2021Q3 elox Gain On Extinguishment Of Debt
GainOnExtinguishmentOfDebt
808000
elox Gain On Extinguishment Of Debt
GainOnExtinguishmentOfDebt
808000
CY2021Q3 elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
268000
elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
268000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
8000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-11000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-22000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-32000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-6000
us-gaap Investment Income Net
InvestmentIncomeNet
-15000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
360000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-321000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-249000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-801000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9885000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6617000
us-gaap Net Income Loss
NetIncomeLoss
-54637000
us-gaap Net Income Loss
NetIncomeLoss
-28450000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86208754
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40142178
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
64428187
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40115351
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9109440
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5643291
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
13
CY2020Q1 us-gaap Severance Costs1
SeveranceCosts1
4000000.0
CY2020Q1 elox Restructuring And Related Cost Stock Based Compensation Expense
RestructuringAndRelatedCostStockBasedCompensationExpense
2100000
CY2020Q1 elox Restructuring And Related Costs Severance Cost Payment Period
RestructuringAndRelatedCostsSeveranceCostPaymentPeriod
P1Y
CY2020Q3 us-gaap Restructuring Charges
RestructuringCharges
1870000
CY2020Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
1293000
CY2020Q3 us-gaap Restructuring Reserve
RestructuringReserve
577000

Files In Submission

Name View Source Status
0001564590-21-055313-index-headers.html Edgar Link pending
0001564590-21-055313-index.html Edgar Link pending
0001564590-21-055313.txt Edgar Link pending
0001564590-21-055313-xbrl.zip Edgar Link pending
elox-10q_20210930.htm Edgar Link pending
elox-10q_20210930_htm.xml Edgar Link completed
elox-20210930.xsd Edgar Link pending
elox-20210930_cal.xml Edgar Link unprocessable
elox-20210930_def.xml Edgar Link unprocessable
elox-20210930_lab.xml Edgar Link unprocessable
elox-20210930_pre.xml Edgar Link unprocessable
elox-ex101_64.htm Edgar Link pending
elox-ex311_9.htm Edgar Link pending
elox-ex312_7.htm Edgar Link pending
elox-ex321_8.htm Edgar Link pending
elox-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending